source
- AstraZeneca outlines restructuring as earnings show cost cuts, while Alnylam slides and Regeneron posts record quarterAstraZeneca said it will redeploy resources through a new restructuring program aimed at cutting costs while staying on track to hit its long‑term revenue goal of $80 billion by 2030. The company h…
- FDA issues draft guidance to streamline approval of personalized gene therapiesThe FDA released a draft guidance that outlines an "adapted pathway" for regulating gene‑edited medicines. The new framework is intended to speed the development and approval of personalized gene t…